ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
Universidad de Córdoba
Córdoba, EspañaPublicacións en colaboración con investigadores/as de Universidad de Córdoba (3)
2016
-
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
The Lancet Oncology, Vol. 17, Núm. 6, pp. 791-800
-
Quality indicators to assure and improve cancer care in Spain using the delphi technique
JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558
2015
-
Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study
Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795